Jeffrey Weber

Jeffrey Weber led the pivotal CheckMate-238 phase III trial demonstrating that adjuvant nivolumab is superior to ipilimumab for patients with resected stage IIIB-IIIC or stage IV melanoma, establishing nivolumab as a preferred adjuvant option. His research characterized recurrence-free survival, distant metastasis-free survival, and safety outcomes supporting nivolumab's FDA approval for adjuvant melanoma treatment. He has investigated ctDNA and other molecular residual disease markers as predictive biomarkers for adjuvant therapy outcome and relapse risk in resected melanoma. His contributions to melanoma clinical trials span both targeted therapy and immunotherapy across adjuvant and metastatic settings.